<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254877</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00032774</org_study_id>
    <secondary_id>R01AA018896</secondary_id>
    <nct_id>NCT01254877</nct_id>
  </id_info>
  <brief_title>Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons</brief_title>
  <official_title>Ondansetron Pharmacotherapy for Hazardous Drinking in HIV+, African-American Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed randomized clinical trial will investigate a novel pharmacotherapy for hazardous
      drinking, HIV-infected men and women, using the serotonin receptor (5-HT3) antagonist
      ondansetron. The investigators predict that participants who are treated with active doses of
      ondansetron will reduce their drinking more and show better HIV treatment participation and
      progress compared to participants who are treated with placebo. This study will provide
      important new safety and efficacy results on drinking and HIV outcomes following alcohol
      pharmacotherapy in HIV-infected persons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hazardous drinking is particularly harmful in HIV-infected persons. It impairs the immune
      system, accelerates HIV disease progression, slows initiation of antiretroviral therapy (ART)
      and decreases adherence. Thus, the development of effective alcohol treatments for this
      clinical population is particularly important. The investigators are proposing to investigate
      the effectiveness of ondansetron pharmacotherapy for the treatment of hazardous alcohol use
      and alcohol abuse/dependence among HIV-infected patients. Ondansetron, a 5-HT3 antagonist,
      will be studied for several reasons: 1) evidence of effectiveness in persons who want to
      cut-down or reduce their drinking and who are not abstinent at medication initiation; 2)
      moderate-to-strong effects among early onset problem drinkers, a characteristic that is over
      represented in our clinic patients; 3) a very mild side-effect profile, making it an ideal
      pharmacotherapy candidate in patients who are often receiving multiple other medications with
      significant side-effects; and 4) its primary indication is for treatment of nausea, a common
      side-effect of antiretroviral (ARV) medications.

      The proposed study is a placebo-controlled, randomized clinical trial of ondansetron for the
      treatment of hazardous drinking and alcohol use disorders among HIV-infected patients
      recruited from the Baltimore/Washington area. Participants will be genotyped for a functional
      polymorphism of the serotonin transporter gene. They will be randomized to one of three
      treatment groups: placebo, low dose ondansetron (0.2 mg bid) and moderate dose ondansetron
      (0.8 mg bid). All subjects will undergo 16 weeks of pharmacotherapy in combination with
      medication management, and will be followed for 3 and 6 months after medication has ended.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Alcoholic Containing Drinks Per Drinking Day</measure>
    <time_frame>16 weeks</time_frame>
    <description>The Time-line Follow-back (TLFB; Sobell, Sobell, Leo &amp; Cancilla, 1988) is conducted as an interview administered by trained and certified research staff. The interview obtains participant self-reports of daily drinking, including number and type of alcoholic beverages. These data are used to quantify an individual's drinking pattern including the number of drinks per drinking day and drinking frequency. The TLFB was completed biweekly and quantified over the 16-week medication period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Days/Week Abstinent From Alcohol</measure>
    <time_frame>16 weeks</time_frame>
    <description>The Time-line Follow-back (Sobell, Sobell, Leo &amp; Cancilla, 1988) is used to obtain this secondary dependent measure. Alcohol use will be assessed biweekly and quantified over the 16-week medication period. Number of days/week abstinent from alcohol is calculated as the number of abstinent days divided by the number of study medication days (adjusted for days in confinement (e.g., hospitalization; jail)) and multiplied by 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication Safety</measure>
    <time_frame>16 weeks</time_frame>
    <description>Medication side-effects and adverse events were measured using the Systematic Assessment for Treatment of Emergent Events (SAFTEE). The SAFTEE contains 25 detailed questions that systematically address 29 body systems. A trained interviewer elicits information about onset, duration, pattern, and judgment of attribution. For the present trial outcome, we report number of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Discontinue Due to Side Effects</measure>
    <time_frame>16 weeks</time_frame>
    <description>The investigators will count the number of subjects who discontinue medication during the 16-week intervention period due to complaints of side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol-related Problems</measure>
    <time_frame>16 weeks</time_frame>
    <description>Alcohol-related problems were measured using the Short Inventory of Problems - revised (SIP-R), a self-report inventory of adverse consequences associated with alcohol and drug use. The SIP instructs participants to indicate how often each of 15 consequences has occurred during the past three months (&quot;never,&quot; &quot;once or a few times,&quot; &quot;once or twice a week,&quot; &quot;daily or almost daily&quot;; scored 0-3). Item responses are summed to produce a total score and five subscale scores. Total scores range from 0 - 45.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Medication Adherence</measure>
    <time_frame>16 weeks</time_frame>
    <description>The investigators will obtain patient self reports of the number of HIV medication doses taken as a function of the total number of doses prescribed. The adherence measure is expressed as the % of prescribed doses.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Alcohol Abuse</condition>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo Ondansetron - sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is an oral preparation made to appear and taste like the active drug preparation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose ondansetron (0.2 mg bid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>moderate dose ondansetron (0.8 mg bid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>ondansetron 0.2 mg bid, oral preparation, 16 weeks</description>
    <arm_group_label>low dose ondansetron (0.2 mg bid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo ondansetron</intervention_name>
    <description>Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.</description>
    <arm_group_label>Placebo Ondansetron - sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration</description>
    <arm_group_label>moderate dose ondansetron (0.8 mg bid)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be at least 18 years old and HIV-infected

          -  All subjects will be actively drinking at hazardous levels (1) AUDIT score =&gt; 4 for
             women or =&gt;8 for men, or 2) =&gt; 2 binge drinking episodes/month, or 3) &gt;7 drinks/week
             for women or &gt;14 drinks/week for men)

        Exclusion Criteria:

          -  Liver Function Tests (LFTs) &gt; 5 X normal

          -  Magnesium or potassium &gt; 3 X normal

          -  Qtc =&gt; .460 and or a family history of long QT syndrome (LQT)

          -  Inability to read and comprehend English

          -  Actively psychotic or other severe mental health symptoms that would prevent
             appropriate participation

          -  Current enrollment in alcoholism treatment program

          -  Pregnancy; Ondansetron is currently a category B drug. While animal data have not
             identified any harmful effects to mother or fetus, there have not been adequate human
             controlled trials to recommend routine use in this population
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary E McCaul, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000 Aug 23-30;284(8):963-71.</citation>
    <PMID>10944641</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <results_first_submitted>January 29, 2018</results_first_submitted>
  <results_first_submitted_qc>March 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2018</results_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>357 persons signed informed consent; 205 were randomized. 137 exclusions were mainly due to insufficient alcohol use (as determined by self-report or biomarker), abnormal QT interval, or significant mental health symptoms that precluded assessment completion. An additional 13 participants withdrew, were discontinued by the investigators or died.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Ondansetron - Sugar Pill</title>
          <description>Placebo is an oral preparation made to appear and taste like the active drug preparation.
placebo ondansetron: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Ondansetron (0.2 mg Bid)</title>
          <description>ondansetron: ondansetron 0.2 mg bid, oral preparation, 16 weeks</description>
        </group>
        <group group_id="P3">
          <title>Moderate Dose Ondansetron (0.8 mg Bid)</title>
          <description>Ondansetron: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Ondansetron - Sugar Pill</title>
          <description>Placebo is an oral preparation made to appear and taste like the active drug preparation.
placebo ondansetron: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Ondansetron (0.2 mg Bid)</title>
          <description>ondansetron: ondansetron 0.2 mg bid, oral preparation, 16 weeks</description>
        </group>
        <group group_id="B3">
          <title>Moderate Dose Ondansetron (0.8 mg Bid)</title>
          <description>Ondansetron: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="205"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.7" spread="8.7"/>
                    <measurement group_id="B2" value="48.7" spread="8.2"/>
                    <measurement group_id="B3" value="47.8" spread="9.5"/>
                    <measurement group_id="B4" value="48.7" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of drinks per drinking day</title>
          <units>standard alcohol drink</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.1" spread="5.5"/>
                    <measurement group_id="B2" value="10.5" spread="7.7"/>
                    <measurement group_id="B3" value="10.0" spread="8.7"/>
                    <measurement group_id="B4" value="9.9" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of days abstinent from alcohol/week</title>
          <units>days/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="1.9"/>
                    <measurement group_id="B2" value="3.0" spread="2.1"/>
                    <measurement group_id="B3" value="3.3" spread="1.9"/>
                    <measurement group_id="B4" value="3.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Alcoholic Containing Drinks Per Drinking Day</title>
        <description>The Time-line Follow-back (TLFB; Sobell, Sobell, Leo &amp; Cancilla, 1988) is conducted as an interview administered by trained and certified research staff. The interview obtains participant self-reports of daily drinking, including number and type of alcoholic beverages. These data are used to quantify an individual’s drinking pattern including the number of drinks per drinking day and drinking frequency. The TLFB was completed biweekly and quantified over the 16-week medication period</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Ondansetron - Sugar Pill</title>
            <description>Placebo is an oral preparation made to appear and taste like the active drug preparation.
placebo ondansetron: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ondansetron (0.2 mg Bid)</title>
            <description>ondansetron: ondansetron 0.2 mg bid, oral preparation, 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Moderate Dose Ondansetron (0.8 mg Bid)</title>
            <description>Ondansetron: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Alcoholic Containing Drinks Per Drinking Day</title>
          <description>The Time-line Follow-back (TLFB; Sobell, Sobell, Leo &amp; Cancilla, 1988) is conducted as an interview administered by trained and certified research staff. The interview obtains participant self-reports of daily drinking, including number and type of alcoholic beverages. These data are used to quantify an individual’s drinking pattern including the number of drinks per drinking day and drinking frequency. The TLFB was completed biweekly and quantified over the 16-week medication period</description>
          <units>Standard alcohol drinks per drinking day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="3.8"/>
                    <measurement group_id="O2" value="6.1" spread="4.3"/>
                    <measurement group_id="O3" value="5.9" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Days/Week Abstinent From Alcohol</title>
        <description>The Time-line Follow-back (Sobell, Sobell, Leo &amp; Cancilla, 1988) is used to obtain this secondary dependent measure. Alcohol use will be assessed biweekly and quantified over the 16-week medication period. Number of days/week abstinent from alcohol is calculated as the number of abstinent days divided by the number of study medication days (adjusted for days in confinement (e.g., hospitalization; jail)) and multiplied by 7.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Ondansetron - Sugar Pill</title>
            <description>Placebo is an oral preparation made to appear and taste like the active drug preparation.
placebo ondansetron: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ondansetron (0.2 mg Bid)</title>
            <description>ondansetron: ondansetron 0.2 mg bid, oral preparation, 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Moderate Dose Ondansetron (0.8 mg Bid)</title>
            <description>Ondansetron: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days/Week Abstinent From Alcohol</title>
          <description>The Time-line Follow-back (Sobell, Sobell, Leo &amp; Cancilla, 1988) is used to obtain this secondary dependent measure. Alcohol use will be assessed biweekly and quantified over the 16-week medication period. Number of days/week abstinent from alcohol is calculated as the number of abstinent days divided by the number of study medication days (adjusted for days in confinement (e.g., hospitalization; jail)) and multiplied by 7.</description>
          <units>days/week abstinent from alcohol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="2.2"/>
                    <measurement group_id="O2" value="4.9" spread="2.0"/>
                    <measurement group_id="O3" value="4.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Safety</title>
        <description>Medication side-effects and adverse events were measured using the Systematic Assessment for Treatment of Emergent Events (SAFTEE). The SAFTEE contains 25 detailed questions that systematically address 29 body systems. A trained interviewer elicits information about onset, duration, pattern, and judgment of attribution. For the present trial outcome, we report number of events.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Ondansetron - Sugar Pill</title>
            <description>Placebo is an oral preparation made to appear and taste like the active drug preparation.
placebo ondansetron: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ondansetron (0.2 mg Bid)</title>
            <description>ondansetron: ondansetron 0.2 mg bid, oral preparation, 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Moderate Dose Ondansetron (0.8 mg Bid)</title>
            <description>Ondansetron: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Safety</title>
          <description>Medication side-effects and adverse events were measured using the Systematic Assessment for Treatment of Emergent Events (SAFTEE). The SAFTEE contains 25 detailed questions that systematically address 29 body systems. A trained interviewer elicits information about onset, duration, pattern, and judgment of attribution. For the present trial outcome, we report number of events.</description>
          <units>number of events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="11.1"/>
                    <measurement group_id="O2" value="12.4" spread="13.4"/>
                    <measurement group_id="O3" value="11.0" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Discontinue Due to Side Effects</title>
        <description>The investigators will count the number of subjects who discontinue medication during the 16-week intervention period due to complaints of side effects.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Ondansetron - Sugar Pill</title>
            <description>Placebo is an oral preparation made to appear and taste like the active drug preparation.
placebo ondansetron: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ondansetron (0.2 mg Bid)</title>
            <description>ondansetron: ondansetron 0.2 mg bid, oral preparation, 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Moderate Dose Ondansetron (0.8 mg Bid)</title>
            <description>Ondansetron: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Discontinue Due to Side Effects</title>
          <description>The investigators will count the number of subjects who discontinue medication during the 16-week intervention period due to complaints of side effects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alcohol-related Problems</title>
        <description>Alcohol-related problems were measured using the Short Inventory of Problems - revised (SIP-R), a self-report inventory of adverse consequences associated with alcohol and drug use. The SIP instructs participants to indicate how often each of 15 consequences has occurred during the past three months (“never,” “once or a few times,” “once or twice a week,” “daily or almost daily”; scored 0-3). Item responses are summed to produce a total score and five subscale scores. Total scores range from 0 - 45.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Ondansetron - Sugar Pill</title>
            <description>Placebo is an oral preparation made to appear and taste like the active drug preparation.
placebo ondansetron: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ondansetron (0.2 mg Bid)</title>
            <description>ondansetron: ondansetron 0.2 mg bid, oral preparation, 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Moderate Dose Ondansetron (0.8 mg Bid)</title>
            <description>Ondansetron: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol-related Problems</title>
          <description>Alcohol-related problems were measured using the Short Inventory of Problems - revised (SIP-R), a self-report inventory of adverse consequences associated with alcohol and drug use. The SIP instructs participants to indicate how often each of 15 consequences has occurred during the past three months (“never,” “once or a few times,” “once or twice a week,” “daily or almost daily”; scored 0-3). Item responses are summed to produce a total score and five subscale scores. Total scores range from 0 - 45.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="7.3"/>
                    <measurement group_id="O2" value="7.5" spread="7.9"/>
                    <measurement group_id="O3" value="8.3" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Medication Adherence</title>
        <description>The investigators will obtain patient self reports of the number of HIV medication doses taken as a function of the total number of doses prescribed. The adherence measure is expressed as the % of prescribed doses.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Ondansetron - Sugar Pill</title>
            <description>Placebo is an oral preparation made to appear and taste like the active drug preparation.
placebo ondansetron: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Ondansetron (0.2 mg Bid)</title>
            <description>ondansetron: ondansetron 0.2 mg bid, oral preparation, 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>Moderate Dose Ondansetron (0.8 mg Bid)</title>
            <description>Ondansetron: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Medication Adherence</title>
          <description>The investigators will obtain patient self reports of the number of HIV medication doses taken as a function of the total number of doses prescribed. The adherence measure is expressed as the % of prescribed doses.</description>
          <units>percentage of prescribed doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.4" spread="31.6"/>
                    <measurement group_id="O2" value="87.6" spread="37.6"/>
                    <measurement group_id="O3" value="85.4" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Ondansetron - Sugar Pill</title>
          <description>Placebo is an oral preparation made to appear and taste like the active drug preparation.
placebo ondansetron: Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Ondansetron (0.2 mg Bid)</title>
          <description>ondansetron: ondansetron 0.2 mg bid, oral preparation, 16 weeks</description>
        </group>
        <group group_id="E3">
          <title>Moderate Dose Ondansetron (0.8 mg Bid)</title>
          <description>Ondansetron: Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiovascular event</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Alcohol Intoxication</sub_title>
                <description>Acute alcohol intoxication treated in the Emergency Dept or inpatient hospitalization</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Psychiatric disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia/Respiratory Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol intoxication/withdrawal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough/cold symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Drinking data are based on patient self-report.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mary E McCaul</name_or_title>
      <organization>JohnHopkinsU</organization>
      <phone>410-955-9526</phone>
      <email>mmccaul1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

